biote (BTMD) to Release Earnings on Tuesday

biote (NASDAQ:BTMD) is set to post its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect biote to post earnings of $0.05 per share for the quarter. biote has set its FY 2024 guidance at EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

biote (NASDAQ:BTMD) last announced its quarterly earnings results on Tuesday, March 12th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.06. The company had revenue of $45.70 million during the quarter, compared to analysts’ expectations of $45.50 million. biote had a negative return on equity of 45.10% and a net margin of 1.79%. On average, analysts expect biote to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

biote Trading Up 4.0 %

Shares of BTMD stock opened at $6.01 on Friday. The stock has a 50 day moving average of $5.86 and a 200 day moving average of $5.18. The stock has a market cap of $447.93 million, a P/E ratio of -27.32 and a beta of 0.87. biote has a twelve month low of $3.65 and a twelve month high of $8.22.

Wall Street Analysts Forecast Growth

BTMD has been the topic of a number of recent analyst reports. Truist Financial decreased their target price on biote from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, January 18th. B. Riley initiated coverage on shares of biote in a research report on Tuesday, February 20th. They set a “buy” rating and a $9.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of biote in a research report on Thursday, February 1st. They set a “buy” rating and a $6.55 price objective for the company. Finally, Roth Mkm restated a “buy” rating and set a $9.00 price objective (up from $8.00) on shares of biote in a research report on Wednesday, March 13th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, biote has an average rating of “Buy” and a consensus price target of $8.11.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.